Cytomegalovirus (CMV) Reactivation in Post-allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) Patients: Salvage and Prophylactic Treatments of Nilotinib.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 26 Dec 2012 Planned End Date changed from 1 Dec 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 14 Dec 2010 New trial record